Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients

American Journal of Nephrology

Volumn 19, Issue 3, 1999, Pages 411-415

  Capone, Domenico ^a   Stanziale, Pasquale ^b   Gentile, Antonio ^a   Imperatore, Paola ^b   Pellegrino, Tommaso ^a   Basile, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cyclosporin; Drug interaction; Hydroxymethylglutaryl coenzyme A reductase inhibitors Hyperlipidemia; Renal transplantation

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PRAVASTATIN; PREDNISONE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PRAVASTATIN; SIMVASTATIN;

EID: 0033038538     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013487     Document Type: Article

References (28)

1. Ibels LS, Alfrey AC, Weil R: Hyperlipidemia in adult, pediatric and diabetic renal transpant recipients. Am J Med 1978;64:634-642.
2. Ballantyne CM, Jones PH, Payton-Ross C, Patsch W, Short HD III, Noon GP, Gotto AM Jr, DeBakey ME, Young JB: Hyperlipidemia following heart transplantation: Natural history and intervention with mevinolin (lovastatin). Transplant Proc 1987;19:60-62.
3. Bieber CP, Hunt SA, Schwinn DA, Jamieson SA, Reitz BA, Oyer PE, Shumway NE, Stinson EB: Complications in long-term survivors of cardiac transplantation. Transplant Proc 1981; 13:207-211.
4. Gunnarsson R, Lofmark R, Nordlander R, Nyquist O, Groth CG: Acute myocardial infarction in renal transplant recipients: Incidence and prognosis. Eur Heart J 1984;5:218-221.
5. Traindl O, Reading S, Franz M, Falger S, Klauser R, Gisinger J, Widhalm K, Kovarik J: Low-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporine A. Transplant Proc 1992;24:2745-2747.
6. Yoshimura N, Ohmori Y, Tsuji T, Oka T: Effect of pravastatin on renal transplant recipients treated with cyclosporine: 4-year follow-up. Transplant Proc 1994;26:2632-2633.
7. Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ: Cholesterol-lowering therapy after heart transplantation: A 12-month randomized trial. J Heart Lung Transplant 1995;14:613-622.
8. Pisanti N, Stanziale P, Imperatore P, D'Alessandro R, De Marino V, Capone D, De Marino V: Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients. Am J Nephrol 1998;18:199-203.
9. Study Group of the European Atherosclerosis Society: The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600.
10. Pirsch JD, Armbrust MJ, Knechtle SJ, D'Alessandro M, Sollinger HW, Heisey DM, Belzer FO: Obesity as a risk factor following renal transplantation. Transplantation 1995;59: 631-633.
11. Lopez-Miranda J, Pérez-Jiménez F, Torres A, Espino-Montoro A, Gomez P, Hidalgo-Rojas L, Ordovas JM, Jimenez-Pereperez JA: Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992;25:379-386.
12. Loepz-Miranda J, Pérez-Jiménez F, Gomez-Gerique JA, Espino-Montoro A, Hidalgo-Rojas L, Pedreno J, Jimenez-Pereperez JA: Effect of cyclosporin on plasma lipoprotein lipase activity in rats. Clin Biochem 1994;27:387-394.
13. Stiller MJ, Pak GH, Kenny C, Jondreau L, Davis I, Wachsman S, Shupack JL: Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. J Am Acad Dermatol 1992;27:434-438.
14. Hsu I, Spinler SA, Johnson NE: Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-759.
15. Witztum JL: Drugs used in the treatment of hyperlipoproteinemias; in Hardman JG, Limbird LE (eds): The Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 1996, chap 36, pp 875-897.
16. Capone D, Aiello C, Santoro GA, Gentile A, Stanziale P, D'Alessandro R, Imperatore P, Basile V: Drug interaction between cyclosporine and two antimicrobial agents, josamycin and rifampicin, in organ-transplanted patients. Int J Clin Pharmacol Res 1996;16:73-76.
17. Capone D, De Marino V, Fontana R, Notaro R, De Marino V, Pisanti N: Effects of different routes of cyclosporin A administration on blood levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1997;19:369-372.
18. Lemaire M, Tillement JP: Role of lipoproteins and erythrocytes in the vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 1982;34:715-718.
19. Nemunaitis J, Deeg HJ, Yee GC: High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia. Lancet 1986;ii:744-745.
20. Vanhaecke J, Van Cleemput J, Van Lierde J, Daenen W, De Geest H: Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994;15:42-45.
21. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH, Teraski PI, Danovitch GM: The effect of pravastatin on acute rejection after kidney transplantation: A pilot study. Transplantation 1996;27:1469-1474.
22. Anguita M, Alonso Pulpon L, Arizon JM, Cavero MA, Valles F, Segovia J, Perez-Jimenez F, Crespo M, Concha M: Comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronray artery disease. Am J Cardiol 1994;74:776-779.
23. Cheung AK, DeVault GA Jr, Gregory MC: A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993;3:1884-1891.
24. Li PK, Mak TW, Chan TH, Wang A, Lam CW, Lai KN: Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation 1995;15:652-656.
25. Holdaas H, Hartmann A, Stenstrom J, Dahl KJ, Borge M, Pfister P: Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995;76:102-106.
26. Regazzi MB, Iacona I, Campana C, Gavazzi A, Viganò M, Perani G: Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 1994;26: 2644-2645.
27. Campana C, Iacona I, Regazzi MB, Gavazzi A, Perani G, Raddato V, Montemartini C, Vigano M: Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995;29:235-239.
28. Katznelson S, Kobashigawa JA: Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int 1995;52(suppl):112-115.